Terumo (OTCMKTS:TRUMY) Stock Crosses Below Fifty Day Moving Average - Here's What Happened

Key Points

• Terumo Corp. shares dropped below their 50-day moving average of $17.21, hitting a low of $16.11 during trading, with the last price recorded at $16.58.
• The company recently reported earnings of $0.20 per share for the quarter, surpassing expectations but falling short on revenue with $1.76 billion against an estimate of $1.80 billion.
• Terumo has a market capitalization of $24.55 billion, with notable financial ratios like a price-to-earnings ratio of 29.09 and a debt-to-equity ratio of 0.07.

Terumo Corp. (OTCMKTS:TRUMY - Get Free Report) shares crossed below its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $17.21 and traded as low as $16.11. Terumo shares last traded at $16.58, with a volume of 101,751 shares trading hands.

Terumo Trading Down 1.3%

The company has a market capitalization of $24.55 billion, a price-to-earnings ratio of 29.09 and a beta of 0.79. The company has a quick ratio of 1.53, a current ratio of 2.64 and a debt-to-equity ratio of 0.07. The company's 50 day simple moving average is $17.21 and its two-hundred day simple moving average is $17.85.

Terumo (OTCMKTS:TRUMY - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported $0.20 earnings per share for the quarter, beating the consensus estimate of $0.17 by $0.03. The company had revenue of $1.76 billion during the quarter, compared to the consensus estimate of $1.80 billion. Terumo had a net margin of 12.09% and a return on equity of 9.19%.

About Terumo

Terumo Corporation engages in the manufacture and sale of medical products and equipment in Japan, Europe, China, the United States, Asia, and internationally. The company operates through three segments: Cardiac and Vascular Company, Medical Care Solutions Company, and Blood and Cell Technologies Company.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.